Current Discounted Rates End In:
- 00DAYS
- 00HRS
- 00MINS
- 00SECS
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Centerkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day One
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference - Day One
search
Streams
7:30am - 7:45am15 mins
Registration
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 1
Nagase Breakfast Spotlight Presentation
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 2
Breakfast Spotlight Presentation
7:45am - 8:15am30 mins
Breakfast Spotlight Presentations 3
Breakfast Spotlight Presentation
8:25am - 8:30am5 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Chairman’s Remarks
- Claus Rentel, PhD - Vice President, Analytical Development/QC, Ionis Pharmaceuticals, Inc.
8:25am - 8:30am5 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
Chairman’s Remarks
- Troels Koch, PhD - Industry Expert, Industry Expert
8:25am - 8:30am5 mins
Peptides TRACK: Peptides for COVID-19 Therapy
Chairman’s Remarks
- Trishul Shah, MS - Director Business Development, PolyPeptide Group
8:25am - 8:30am5 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
Chairman’s Remarks
- Nicole Roth, Ph.D. - Senior Scientist, CureVac AG
8:30am - 9:00am30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Analytical Method Development for Critical Impurities in Phosphoramidites
- Dennis Rhodes - Assistant Director, Analytical Development and QC, Ionis Pharmaceuticals
8:30am - 9:00am30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
Targeting ANGPTL4 in the Liver with ASO – A Novel Treatment for Cardiometabolic Disease
- Stefan Nilsson, Ph.D. - CEO, Lipigon Pharmaceuticals AB
8:30am - 9:00am30 mins
Peptides TRACK: Peptides for COVID-19 Therapy
Treatment with Vasoactive Intestinal Peptide (aviptadil) is Life-saving in Patients with Critical COVID-19
- Jonathan Javitt - Founder & Chief Executive Officer, NeuroRx Inc
8:30am - 9:00am30 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
Programming mRNA for Cancer Immunotherapy
- Tasuku Kitada, Ph.D. - President and Head of R&D, Strand Therapeutics
9:00am - 9:30am30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Automated Online UPLC and Data Processing for Oligonucleotide Synthesis and Purification Monitoring
- Andrew Argo - Scientist I, Quality Control Analytical Technology, Biogen
9:00am - 9:30am30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
U1 Adaptors Bioconjugates for Targeted Gene Silencing in Extrahepatic Tissues
- P. Peter Ghoroghchian, M.D., Ph.D. - President and CEO, Silagene, Inc.
9:00am - 9:30am30 mins
Peptides TRACK: Peptides for COVID-19 Therapy
Developing a Highly Conserved, Non-human-like, and Cross-reactive SARS-CoV-2 Peptide-based COVID-19 Vaccine
- Annie De Groot, M.D. - Founder, CEO and CSO, Epivax, Inc.
9:00am - 9:30am30 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
A Novel Vaccine Approach Using Messenger RNA‐Lipid Nanoparticles: Preclinical and Clinical Perspective
- Ying Tam, Ph.D. - Chief Scientific Officer, Acuitas Therapeutics, Inc.
9:30am - 10:00am30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Control of GalNAc siRNA Conjugates
- Adel Rafai Far, Ph.D. - Principal Fellow, Chemical and Analytical R&D, Novartis Pharmaceuticals
9:30am - 10:00am30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
A Novel, RNA-based Anti-viral Approach to Limit BK Virus Propagation in Immunocompromised Patients
- Eric van der Veer, Ph.D. - Chief Scientific Officer, Hybridize Therapeutics
9:30am - 10:00am30 mins
Peptides TRACK: Peptides for COVID-19 Therapy
When the Process Doesn't Fit - 8 Weeks to Build a Purification Suite to Support A Critical Covid-19 Vaccine Adjuvant
- Tim Culbreth - Site Director, Polypeptide
9:30am - 10:00am30 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
Preclinical Immunogenicity Characterization of ARCT-021 SARS-CoV-2 Vaccine
- Sean Sullivan, Ph.D. - Executive Director, Process Development, Arcturus Therapeutics
10:00am - 10:45am45 mins
Networking Refreshment Break in Poster and Exhibit Hall
10:45am - 11:15am30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Analytical Method Development of Complementary Related Organic Impurity Methods for Oligonucleotides
- Chris Gripton, Ph.D. - Principal Scientist, GSK Medicines Research Centre
10:45am - 11:15am30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
Platform Optimization to Enable Therapeutic Development of ADAR-mediated RNA editing
- Stuart Milstein, Ph.D. - VP Platform Biology, Korro Bio
10:45am - 11:15am30 mins
Peptides TRACK: Peptide Discovery and Development
Solid-Phase Peptide Synthesis Using a Four-Dimensional Protecting Group Scheme
- Fernando Albericio, PhD - Research Professor, School of Chemistry, University of Kwazulu-Natal
10:45am - 11:15am30 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
Subcutaneous Administration of mRNA LNPs to Achieve Systemic Exposures of Protein
- Nigel Davies - Scientist, AstraZeneca
11:15am - 11:45am30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Identification and Quantitation of Thermal Degradation Products of Antisense Oligonucleotides (ASOs) Enables Understanding of Degradation Mechanism
- Rasika Phansalkar, Ph.D. - Scientist I, Technical Development, Biogen
11:15am - 11:45am30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
Speaker TBA
11:15am - 11:45am30 mins
Peptides TRACK: Peptide Discovery and Development
Discovery and Optimization of Long-acting, Unimolecular Peptide Triple Agonists of the GLP-1, GIP, and Glucagon Receptors
- Patrick Knerr, Ph.D. - Research Scientist II - Chemistry, Novo Nordisk Research Center Indianapoli
11:15am - 11:45am30 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
A Platform Approach for mRNA Vaccine Development
- Don Parsons, PhD - Head, Early Technical Development and LNP Process, Moderna Therapeutics
11:45am - 12:15pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Analytics of Oligonucleotides
Advancing the Pharmaceutical Science of Lipid Delivery Systems and their Translation to the Clinic
- Angela Wagner, PhD - Associate Principal Scientist, Sterile & Specialty, Merck Sharpe & Dohme
11:45am - 12:15pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Emerging Oligonucleotide Drug Discovery
Speaker TBA
11:45am - 12:15pm30 mins
Peptides TRACK: Peptide Discovery and Development
Oral Delivery of PTH 1-34 in the Treatment of Hypoparathyroidism and Osteoporosis
- Phillip Schwartz, Ph.D. - President of R&D and EVP, Entera Bio Ltd.
11:45am - 12:15pm30 mins
mRNA and Genome Editing TRACK: mRNA Discovery, Delivery and Translation to the Clinic
CMC Regulatory Strategies for mRNA Vaccines
- Paul Dawidcyz - VP, Regulatory Affairs CMC, Moderna Therapeutics
12:15pm - 12:20pm5 mins
Transition to Spotlight Presentation Rooms
Spotlight Presentations
12:20pm - 12:50pm30 mins
Spotlight Presentation 1
Asahi Spotlight Presentation
12:20pm - 12:50pm30 mins
Spotlight Presentation 2
Gyros Spotlight Presentation
12:20pm - 12:50pm30 mins
Spotlight Presentation 3
Phenomenex Spotlight Presentation
12:50pm - 1:55pm65 mins
Networking Luncheon in Poster and Exhibit Hall
1:55pm - 2:00pm5 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Chairman’s Remarks
- Firoz Antia, PhD - Director, Biogen
1:55pm - 2:00pm5 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Chairman’s Remarks
- Punit Seth, PhD - Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
1:55pm - 2:00pm5 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Chairman’s Remarks
- Jesse Dong, Ph.D. - Vice President, Peptide Chemistry, BioNTech
1:55pm - 2:00pm5 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
Chairwoman’s Remarks
- Nicole Roth, Ph.D. - Senior Scientist, CureVac AG
2:00pm - 2:30pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Sustainability Challenges and Opportunities in Oligonucleotide Manufacturing
- Ben Andrews, Ph.D. - Scientific Investigator, GlaxoSmithKline
2:00pm - 2:30pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Old Dogs and New Puppies of Chemical Modifications for RNA Therapeutics
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
2:00pm - 2:30pm30 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Tumor-targeted Radionuclides Using De Novo Macrocyclic Peptide-mimetics
- Deborah Charych, Ph.D. - Chief Technology Officer and Co-founder, RayzeBio, Inc.
2:00pm - 2:30pm30 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
Development of Broadly Protective Influenza Vaccines Using Nucleoside-modified mRNA
- Norbert Pardi, PhD - Research Assistant Professor of Medicine, University of Pennsylvania
2:30pm - 3:00pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Oligonucleotide Starting Materials – Drivers (or Disasters) for Sustainability
- Louis Diorazio, Ph.D. - Principal Scientist, Chemical Development, AstraZeneca
2:30pm - 3:00pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Chemical Modification of Guide RNA in Genome Editing
- Rubina Parmar, PhD - Director, Chemistry, Intellia Therapeutics
2:30pm - 3:00pm30 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Development of Targeted Alpha Therapeutics for the Treatment of Solid Tumors
- John Rhoden, Ph.D. - Director, Preclinical Development, Fusion Pharmaceuticals
2:30pm - 3:00pm30 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
Fully Protective Anti-malaria Immunity by a Self-amplifying RNA Vaccine
- Richard Bucala, M.D., Ph.D. - Professor of Medicine, Pathology, and Epidemiology, Yale University School of Medicine
3:00pm - 3:30pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Delivering the Promise of Nucleic Acid Medicines: The Challenge of Scale Cost and Sustainability
- Paul McCormac, , Ph.D. - SVP Technical Operations, LEXEO Therapeutics
3:00pm - 3:30pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Oligonucleotide Backbone Engineering for Enhancing Metabolic Stability, Potency, and Selectivity of siRNAs
- Ken Yamada, Ph.D. - Assistant Professor, University of Massachusetts Medical School
3:00pm - 3:30pm30 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Targeted Delivery of Radionuclides
- Justyna Kelly - VP, Medical Isotope Development and Operations, POINT Biopharma Inc.
3:00pm - 3:30pm30 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
mRNA Vaccines for Malaria
- Puthupparampil Scaria, Ph.D. - Head, Conjugation Group, NIAID/NIH
3:30pm - 4:15pm45 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Networking Refreshment Break in Poster and Exhibit Hall
3:30pm - 4:15pm45 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
Networking Refreshment Break in Poster and Exhibit Hall
4:15pm - 4:45pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Development of a Scalable Synthesis Process for Oligonucleotides
- Xianglin Shi - Principal Scientist, Biogen
4:15pm - 4:45pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Redefining the Chemical Space for Antisense Therapeutics
- Punit Seth, PhD - Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
4:15pm - 4:45pm30 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
New Peptide Receptor Radionuclide Therapy Theranostic Indications
- Stanley Satz, Ph.D. - Chief Scientific Officer, Advanced Innovative Partners, Inc.
4:15pm - 4:45pm30 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
RNActive® - CureVac’s mRNA Vaccines Against Different Pathogens
- Nicole Roth, Ph.D. - Senior Scientist, CureVac AG
4:45pm - 5:15pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Sustainability Issues to Address for Increased Oligo Manufacturing Volumes (Costs/Strategic/Technical)
- Anthony Scozzari - Senior Vice President, Development Chemistry & Manufacturing, Ionis Pharmaceuticals
4:45pm - 5:15pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Sequence-specific Recognition of Double-stranded RNA by Cationic Nucleobase and Backbone-modified Peptide Nucleic Acids
- Eriks Rozners, Ph.D. - Professor and Chair of Chemistry Department, Binghamton University
4:45pm - 5:15pm30 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Journey Beyond the Margin: Development of Imaging System to Assist Tumor Resections
- Jorge Ferrer, Ph.D. - SVP of Clinical Research and Strategy, Lumicell
4:45pm - 5:15pm30 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
Optimization of LNPs for Improved mRNA Vaccines
- Luis Brito, PhD - Director, Formulation Science, Moderna Therapeutics
5:15pm - 5:45pm30 mins
Oligonucleotide CMC and Targeted Delivery TRACK: Sustainable Manufacturing of Oligos
Speaker TBA
5:15pm - 5:45pm30 mins
Oligonucleotide Discovery to Clinic and CMC TRACK: Nucleic Acid Chemical Modifications
Exploring New Oligonucleotide Backbone Chemistries and Their Deployment to Improve the Properties of Stereopure Oligonucleotides
- Chandra Vargeese, Ph.D. - SVP, Head of Drug Discovery, WAVE Life Sciences
5:15pm - 5:45pm30 mins
Peptides TRACK: Targeted Radioligand Therapies and Tumor Imaging with Peptides and Other Molecules
Panel Discussion with Session Speakers
5:15pm - 5:45pm30 mins
mRNA and Genome Editing TRACK: mRNA Vaccines for Non-COVID-19 Indications
Speaker TBA
5:45pm - 6:45pm60 mins
Party on Lawn D
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams